Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Noa Biran, MD, Susanna Jacobus, David Siegel, MD PhD, Natalie Scott Callander, MD, Rafael Fonseca, MD, David H. Vesole, MD, Michael E. Williams, MD, Rafat Abonour, MD, Michael S Katz, BS,MBA, S. Vincent Rajkumar, Philip R. Greipp, MD

Blood (2015) 126 (23): 3174.

https://doi.org/10.1182/blood.V126.23.3174.3174

Published: 2015

Journal Articles

Current State of Patient Awareness and Participation in Care for Multiple Myeloma and the Psychophysical Impact of Treatment: An International Internet-Based Study

Sikander Ailawadhi, MD, Abhisek Swaika, MBBS, Pooja Advani, MBBS, Michael S Katz, David O Hodge, Aneel Paulus, MDMS, Nandita Khera, MD MPH, Shahrukh K Hashmi, MD, Gerardo Colon-Otero, MD, Vivek Roy, MD, Asher Chanan-Khan, MD

Blood (2014) 124 (21): 1294.

https://doi.org/10.1182/blood.V124.21.1294.1294

Published: 2014

Journal Articles

Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.

Blood (2012) 120 (21): 3165.

https://doi.org/10.1182/blood.V120.21.3165.3165

Published: 2012

Journal Articles

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Matthias Weiss, MD, PhD, Susanna Jacobus, MS, Lynne I Wagner, PhD, David Cella, PhD, Michael S Katz, BS., MBA, Vincent Rajkumar, MD, Rafael Fonseca, MD

Blood (2011) 118 (21): 4184.

https://doi.org/10.1182/blood.V118.21.4184.4184

Published: 2011

Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial

David Samuel diCapua Siegel, MD, PhD, Susanna Jacobus, MS, S. Vincent Rajkumar, MD, Rafat Abonour, MD, Natalie Scott Callander, MD, Michael S Katz, BS., MBA, Rafael Fonseca, David H. Vesole, MD, PhD, On behalf of the Eastern Cooperative Oncology Group

Blood (2010) 116 (21): 38.

https://doi.org/10.1182/blood.V116.21.38.38

Published: 2010

Journal Articles

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

David H. Vesole, MD, PhD, Martin M Oken, MD, Charles Heckler, Philip R. Greipp, MD, Michael S Katz, BS., MBA, Susanna Jacobus, MS, Gary R Morrow, PhD, MS, On Behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group

Blood (2010) 116 (21): 3017.

https://doi.org/10.1182/blood.V116.21.3017.3017

Published: 2010

Journal Articles

Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)

David H. Vesole, MD, PhD, Susanna Jacobus, MS, S. Vincent Rajkumar, MD, Rafat Abonour, MD, Natalie Scott Callander, MD, Philip R. Greipp, MD, Rafael Fonseca, Michael S Katz, BS., MBA, David Samuel diCapua Siegel, MD, PhD, On Behalf of the Eastern Cooperative Oncology Group

Blood (2010) 116 (21): 308.

https://doi.org/10.1182/blood.V116.21.308.308

Published: 2010

Journal Articles

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

Brian G.M. Durie, MD, Brian Van Ness, PhD, Christine Ramos, PhD, Owen Stephens, Majda Haznadar, Antje Hoering, PhD, Jeff Haessler, PhD, Michael S. Katz, BS, Gregory R. Mundy, MD, Robert A. Kyle, MD, Gareth J. Morgan, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, John Shaughnessy, Jr., PhD

Blood (2007) 110 (11): 816.

https://doi.org/10.1182/blood.V110.11.816.816

Published: 2007

NARROW

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Current State of Patient Awareness and Participation in Care for Multiple Myeloma and the Psychophysical Impact of Treatment: An International Internet-Based Study

Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only